Autopsy report · NCT04048707

Angiotensin 2 for Hepatorenal Syndrome

“Funding issues; the study was never started”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of California, Los Angeles

Sponsor type

University, hospital or other

Conditions

Hepatorenal Syndrome; Cirrhosis; Kidney Failure, Acute

Interventions

Angiotensin II; Midodrine; Octreotide; Albumin solution

Participants

0

Trials that died the same way

• Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
  “The study did not get financed. Never got started.” (87% match in meaning)
• GO-203-2C + Bortezomib For Relapsed Or Refractory MM
  “Study was never open due to lack of funding” (85% match in meaning)
• Dim Light at Night in Patients With Obstructive Sleep Apnea
  “The study was stopped due to lack of funding.” (83% match in meaning)
• Regulation of the Release of Inflammatory Mediators From Blood Leukocytes
  “No funding for the study” (83% match in meaning)
• Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
  “The study was stopped because of lack of funding.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.